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Stroke is a serious, life-threatening medical condition that occurs when the blood supply to a part of the brain is 
restricted. Stroke is the ith most frequent cause of death globally and a leading cause of serious long-term disa-
bility1,2. here has been a signiicant worldwide increase in stroke burden over the last two and half decades. here 
has been a signiicant increase in stroke burden in the world over the last two and half decades. Stroke treatment 
in the acute phase generally includes medicines to lyse and/or remove blood clots. Currently, the only approved 
drug for acute stroke is recombinant tissue plasminogen activator (rtPA, alteplase), which increases the risk for 
subsequent hemorrhage and has a limited time window for administration. As a consequence, only a small per-
centage of patients receive rtPA treatment. here are no approved treatments for the numerous damaging patho-
logical processes that are activated during stroke. hese include excitotoxicity, oxidative stress, apoptosis, edema, 
inlammation, and impairment of the blood-brain barrier (BBB). he development of a neuroprotective treatment 
that has the ability to favorably inluence the multiple deleterious mechanisms that are activated during stroke is 
an urgent clinical need. Moreover, combining neuroprotection with reperfusion therapy has been proposed as a 
strategy in the development of acute stroke therapies3.
Carnosine is an endogenous pleiotropic dipeptide consisting of alanine and histidine that is expressed in many 
tissues of the body, including the central nervous system (CNS)4–6. Recent studies have shown that carnosine 
has beneicial efects against various diseases including brain-related disorders, and that carnosine shows robust 
neuroprotective efects in acute ischemic stroke4,7–10. It exhibits many properties that make it an attractive neuro-
protective agent including antioxidant, anti-excitotoxic, anti-matrix metalloproteinase, and metal ion chelating 
and intracellular pH bufering properties7,11,12. Despite its potent biological beneit against ischemic stroke in 
animal models, clinical translation of this compound has been impeded by the large doses needed (500-1,000 mg/
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kg) for eicacy6,13. High doses may be required possibly due to the rapid breakdown of carnosine ater systemic 
administration due to the action of serum and cellular proteases14. he use of carriers that are able to prevent 
serum degradation of carnosine, as well as target delivery to the CNS may signiicantly reduce the doses needed 
and therefore could help in translating the promising preclinical indings into clinical studies.
Polymersomes are synthetic vesicles formed by the self-assembly of amphiphilic co-polymers in aquatic con-
ditions15. In this study we have used pH-sensitive poly(2-(diisopropylamino)ethyl methacrylate) (PDPA) based 
polymersomes, poly[oligo(ethylene glycol) methyl methacrylate] (POEGMA) which have been functionalized 
by incorporating Angiopep-2 on to their surface, targeting lipoprotein receptor related protein-1 (LRP-1) which 
is one of the highly expressed receptors in the BBB16–18. We have previously shown that these POEGMA-PDPA 
polymersomes functionalized with Angiopep-2, enables non-invasive entry of polymersomes across the BBB by 
transcytosis and the delivery of drugs and macromolecular cargo such as antibodies to the cellular cytoplasm of 
CNS cells15,19.
In this study, we assessed the neuroprotective potential of carnosine encapsulated in polymersomes with 
Angiopep-2 for LRP-1-mediated targeted delivery to the CNS in experimental stroke. We hypothesized that the 
delivery of carnosine encapsulated within Angiopep-2-POEGMA-PDPA would be able achieve the same ther-
apeutic efects observed with free carnosine at a much lower dosage, due to the targeting peptide and due to 
encapsulation of carnosine protecting it from premature degradation. We also evaluated the time dependent 
distribution of targeted and non-targeted carnosine encapsulated polymersomes in brain and other tissues.

ǦǤ he formation of 
POEGMA–PDPA polymersomes were carried out by the hydration of a polymer ilm at pH 7.4. Transmission 
electron microscopy (TEM) conirmed that POEGMA–PDPA copolymer alone or in combination with carnosine 
formed vesicles from the ilm hydration method, resulting in a distribution of nano-polymersome sizes (Fig. 1A). 
Polymersome size, and size preservation ater loading of the drug, was quantiied by measuring the polymersome 
size by dynamic light scattering (DLS). DLS data analysis by the number of vesicles of any given diameter per 
sample demonstrated that the most abundant sizes were similar across all samples (approx. 40–60 nm), for both 
blank (Blank-NPs) and carnosine-loaded polymersomes (CAR-NPs) (Fig. 1B) regardless of Angiopep-2 incorpo-
ration (Brain-targeted (bt-) or Non-targeted (nt-)).
Ǧ
Ǥ To determine the eicacy of polymersomes 
loaded with carnosine, permanent focal ischemia was induced in rats by occlusion of middle cerebral artery 
(MCAo) using an intraluminal monoilament. No signiicant diferences among the experimental groups were 
detected in physiological variables of body weight and rectal temperature (data not shown). Changes in cerebral 
blood low (CBF) before and ater ischemia were not signiicant between the groups (Fig. 2A).
Functional outcomes. Treatment with carnosine (L-CAR sol.; 1,000 mg/kg) at 3 hours ater ischemia onset sig-
niicantly reduced neurological deicits induced by permanent MCAo. Remarkably, bt-CAR-NP exhibited similar 
reduction in neurological deicits at a concentration of 1 mg/kg (Fig. 2B). On the other hand, nt-CAR-NP (1 mg/
kg) did not alter functional outcomes.
Figure 1. Morphology and size distribution of polymersomes (A) Polymersome morphology and size were 
characterized via transmission electron microscopy. Electron micrographs conirm the vesicular structure of all 
polymersome types; bt-Blank-NP, bt-CAR-NP, nt-Blank-NP and nt-CAR-NP, with a distribution of diameters 
within each sample. (B) Polymersome size was assessed by dynamic light scattering (DLS). Size distributions of 
polymersomes were similar across all populations, with an average diameter of around 40 nm.
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Histological outcomes. Post-treatment with carnosine (1,000 mg/kg) or bt-CAR-NP (1 mg/kg) at 3 hours 
ater ischemia signiicantly reduced cerebral infarct volumes in rats following permanent MCAo. Infarct vol-
umes expressed as a percentage of the ischemic hemisphere were 59.6 ± 11.2% and 57.6 ± 16.7% in saline and 
bt-Blank-NP-treated rats respectively (mean ± SD). Rats treated with carnosine (1,000 mg/kg) or bt-CAR-NP 
(1 mg/kg) had signiicantly smaller infarct volumes of 43.1 ± 22.0% and 42.5 ± 19.0%, respectively (mean ± SD).
Ǧ
ȀǤ To determine if bt-CAR-NP reduces brain damage 
induced by ischemia/reperfusion (I/R), a transient rat MCAo model was used. Changes in CBF confirmed 
I/R in the brain (Fig. 3A), which were not significantly different between the treatment groups. At 3 hours 
after ischemia, carnosine (1,000 mg/kg), bt-CAR-NP (1 mg/kg), nt-CAR-NP (1 mg/kg) or corresponding 
vehicle were intravenously administered to rats, and reperfusion was initiated. While nt-CAR-NP (1 mg/
kg) was not effective in reducing infarct volumes (46.3 ± 19.7% in nt-Blank-NP-treated rats vs. 51.8 ± 14.2% 
in nt-CAR-NP-treated rats, mean ± SD), carnosine (1,000 mg/kg) or bt-CAR-nt (1 mg/kg) significantly 
reduced brain infarct volumes after I/R injury (Fig. 3B) (53.4 ± 19.7% in saline-treated rats vs. 36.5 ± 24.1% 
in carnosine-treated rats; 59.3 ± 22.0% in bt-Blank-NP-treated rats vs. 36.9 ± 22.7% bt-CAR-NP-treated 
rats, mean ± SD).
To determine whether the protective efect of bt-CAR-NP is species-speciic, carnosine or bt-CAR-NP were 
administered to mice with transient focal ischemia. Changes in CBF were monitored to conirm I/R injury 
(Fig. 4A). Improvement of functional behavioral deicits and histological brain damage were observed in mice 
treated with carnosine (1,000 mg/kg) or bt-CAR-NP (1 mg/kg) (Fig. 4B,C) (43.4 ± 21.1% in saline-treated 
mice vs. 28.1 ± 19.3% in carnosine-treated mice; 50.7 ± 14.3% in bt-Blank-NP-treated mice vs. 35.2 ± 25.6% 
bt-CAR-NP-treated mice, mean ± SD).
Figure 2. Protective efects of brain-targeted polymersomes with carnosine on neurological function and 
infarct volume in rats with pMCAo Permanent focal ischemia was induced in rats by middle cerebral artery 
occlusion (MCAo) using intraluminal suture. Carnosine (1,000 mg/kg), bt-CAR-NP (1 mg/kg), nt-CAR-NP 
(1 mg/kg) or corresponding vehicles (Saline, bt-Blank-NP and nt-Blank-NP, respectively) were intravenously 
administered at 3 hours ater ischemic onset. (A) Cerebral blood low was monitored before and at the onset 
of pMCAo. Values are mean ± SD. (B) Functional deicits were examined with neurological severity scores 
at 24 hours ater ischemia. (C) Infarct volume was calculated using 2,3,5-triphenyltetrazolium chloride 
(TTC) staining of brain sections. he infarct volume for each section was determined and edema correction 
was performed by measurement of the infarcted and control hemisphere. Representative scanned images 
were shown. Box plot: median, irst and third quartile; whiskers: range. All values were analyzed by one-way 
ANOVA. Diferent letters indicate a statistically signiicant diference (p < 0.05) between experimental groups: 
a vs. rats treated with saline; b vs. rats treated with bt-Blank-NP; c vs. rats treated with nt-Blank-NP; d vs. rats 
treated with nt-CAR-NP. A to C: N = 15 rats/group.
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Figure 3. Protective efects of brain-targeted polymersomes with carnosine on infarct volume in rats with 
tMCAo Transient focal ischemia was induced in rats for ischemia (3 hours)/reperfusion (21 hr) injury (I/R 
injury), and brain damage was calculated with histological analysis. Carnosine (1,000 mg/kg), bt-CAR-NP 
(1 mg/kg), nt-CAR-NP (1 mg/kg) or corresponding vehicles (Saline, bt-Blank-NP and nt-Blank-NP, 
respectively) were intravenously administered at 3 hours ater ischemic onset. (A) Cerebral blood low before 
and ater I/R injury. Values are mean ± SD. (B) Infarct volume was calculated using TTC staining of brain 
sections. Representative scanned images were shown. Box plot: median, irst and third quartile; whiskers: range. 
All values were analyzed by one-way ANOVA. Diferent letters indicate a statistically signiicant diference 
(p < 0.05) between experimental groups: a vs. rats treated with saline; b vs. rats treated with bt-Blank-NP; d vs. 
rats treated with nt-CAR-NP. A and B: N = 15 rats/group.
Figure 4. Improvement of functional and histological damage by brain-targeted polymersomes with carnosine 
in mice with tMCAo Transient focal ischemia (3 hour ischemia/21 hour reperfusion) using intraluminal suture 
was induced in mice. Carnosine (1,000 mg/kg), bt-CAR-NP (1 mg/kg), or corresponding vehicles (Saline and 
bt-Blank-NP, respectively) were intravenously administered at 3 hours ater ischemic onset. (A) Cerebral blood 
low was monitored before and ater I/R injury in mice. Values are mean ± SD. (B) Functional deicits were 
examined with neurological severity scores at 24 hours ater ischemic onset. (C) Infarct volume was calculated 
using TTC staining of brain sections. Representative scanned images were shown. Box plot: median, irst 
and third quartile; whiskers: range. All values are analyzed by one-way ANOVA. Diferent letter indicates a 
statistically signiicant diference (p < 0.05) between experimental groups: a vs. mice treated with saline; b vs. 
mice treated with bt-Blank-NP. A to C: N = 15 mice/group.
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In vivoƪǤ Next, we examined tissue 
distribution of the polymersomes using Cy3-luorescence longitudinally over time. Longitudinal in vivo imaging 
showed that functionalized polymersomes targeting the LRP-1 receptor resulted in accumulation of Cy3 luo-
rescence in the brain. Compared with nt-CAR-NP, the luorescence signal of bt-CAR-NP in the brain increased 
gradually from 3 hours to 48 hours, and decreased at 72 hours ater injection (Fig. 5A). In ex vivo luorescence 
imaging of organs (liver, lung, spleen, heart, kidney, and brain) isolated at 24 hours ater injection, the luorescent 
signal from bt-CAR-NP in brain showed higher intensity than that from nt-CAR-NP (Fig. 5B).

Rapid delivery of systemically administered neuroprotective agents across the BBB into the ischemic brain region 
is a critical component of stroke neurotherapeutic strategies20. One of the reasons for the lack of eicacy of previ-
ously tested neuroprotective agents is the lack of penetration of the agent across the BBB21. Nanomaterial-based 
therapeutics or imaging agents have been approved by US FDA, and interest in these nanomedicines is now 
grwoing22. Recent advances in nanomaterials enable the targeted delivery of therapeutic agents to a speciic organ 
such as brain. Nanoparticles may enhance delivery of neuroprotective drugs that in their free form cannot pass 
the BBB, or do so in very low amounts and thereby not achieving therapeutic concentrations23–25.
Here, we have used pH-sensitive POEGMA –PDPA polymersomes which have been functionalized by incor-
porating LRP-1-targeted Angiopep-2 on to their surface. hese polymersomes have the ability to enter cells via 
receptor-mediated endocytosis, and are then traicked to endosomes where the reduction in pH in the microen-
vironment triggers polymersome dissociation, conformational change and as a consequence, the polymersomes 
disintegrate to produce many individual copolymer chains. his triggers an elevation in the osmotic pressure that 
temporarily lyses the endosomal membrane, allowing the release of encapsulated drug into the cell cytosol26–28.
Using in vivo and ex vivo imaging, (Fig. 5) we tested the ability of LRP-1-targeted (with Angiopep-2) versus 
non-targeted POEGMA-PDPA polymerases to cross the BBB (bt-CAR-NP vs. nt-CAR-NP), Cy3-labeled pol-
ymersomes ater administration in the tail vein of nude mice. Our indings showed strong luorescence of Cy3 
in the brain for up to 48 hours in the group treated with LRP-1-targeted polymersomes. On the other hand, 
non-targeted polymersomes were uniformly distributed throughout the body, but the degree of Cy3 luorescence 
distributed to the brain was relatively low compared to the LRP-1-targeted polymersomes. his suggests that 
the LRP-1-targeted polymersomes had enhanced delivery to the brain. hese data show, for the irst time, that 
targeted polymersomes have the potential to cross the BBB, penetrate brain tissue, and deliver neuroprotective 
cargo. Carnosine encapsulation in LRP-1-targeted polymersomes reduces the dose requirement of carnosine for 
eicacy by at least 3 orders of magnitude. (1 mg/kg intravenous carnosine encapsulated in LRP-1-targeted poly-
mersomes exhibited similar eicacy to 1,000 mg/kg intravenous dosage of carnosine). We have also shown that 
merely encapsulating carnosine in polymersomes without targeting is insuicient for eicacy at the doses tested. 
LRP-1-targeting, which induces transcytosis of the polymersomes across the BBB, is essential for eicacy and 
entry of carnosine into the brain.
here are some limitations of our study. First, we did not test the efect of smaller or larger doses of encapsu-
lated carnosine. It is possible that even smaller doses of carnosine encapsulated in LRP-1-targeted polymersomes 
is eicacious. Similarly, it is possible that non-targeted polymersomes containing doses of carnosine higher than 
1 mg/kg would have been eicacious. Future studies will also need to determine the serum and brain kinetics of 
encapsulated carnosine. To detect in vivo luorescence, nude mice were used to minimize interfering or block-
ing of light by animal hair in this study. Further kinetic studies may need to be done in normal mice to exclude 
any potential efect of immunodeiciency on behavior of carnosine-encapsulated nanopolymersomes. Second, 
diferent treatment regimens and treatment at diferent time points ater onset of ischemia would be interesting 
and useful for therapy development. hird, while this study was designed to demonstrate the proof of concept of 
eicacy of LRP-1-targeted carnosine encapsulation, additional studies in females, older animals, and animals with 
co-morbidities are still needed to fully satisfy the Stroke herapeutic Academic Industry Roundtable (STAIR) 
recommendations29.
Figure 5. In vivo luorescent imaging of mice ater intravenous injection with polymersomes with carnosine 
Cy3-labeled brain-targeted or non-targeted polymersomes were intravenously injected in BALB/c mice. (A) 
Fluorescence signal captured by IVIS Lumina XR Imaging System in whole mice at 0, 0.5, 1, 3, 6, 24, 48 and 
72 hours ater injection with bt-CAR-NP (1 mg/kg) or nt-CAR-NP (1 mg/kg). (B) Ex vivo imaging of isolated 
organs including spleen (S), liver (L), brain (B), heart (H), kidney (K), and lung (Lu) at 24 hours ater injection 
with polymersomes. Representative images are shown. A and B: N = 4.
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In summary, our data show that carnosine encapsulated in LRP-1-targeted polymersomes is efective in reducing 
cerebral injury and improving neurological function ater permanent and transient ischemic stroke. We also show that 
that this novel delivery vehicle for carnosine requires the administration of much lower doses of carnosine, which facili-
tates translation of these preclinical indings to clinical studies. Moreover, our indings open up the possibility that other 
promising neuroprotective agents could be encapsulated in these novel delivery vehicles for targeted CNS delivery.

2-(Methacryloyloxy)ethyl phosphorylcholine (MPC; >99% purity) was donated by Biocompatibles UK Ltd 
(Farnham, UK). 2-(Diisopropylamino)ethyl methacrylate (DPA) was purchased from Scientific Polymer 
Products (Ontario, US). Carnosine, poly(ethylene glycol) methyl ether methacrylate [P(OEG10MA)], copper (I) 
bromide, 2,2′-bipyridine, methanol, bovine liver catalase, glucose oxidase, glucose, 2,3,5-triphenyltetrazolium 
chloride, paraformaldehyde, isopropanol and the gel iltration column for the puriication of the polymersomes 
was made with Sepharose 4B were purchased from Sigma-Aldrich (St. Louis, MO, USA). he silica used for the 
removal of the atom transfer radical polymerization copper catalyst was column chromatography grade silica 
gel 60 (0.063 to 0.200 mm) purchased from Merck (Darmstadt, Germany). 2-(N-morpholino) ethyl 2-bromo- 
2-methylpropanoate initiator was synthesized according to a previously report30. The polymersomes were 
labeled using Cy3 purchased from Lumiprobe (Hunt Valley, MD, USA). PBS was made from Oxoid tablets. 
Silicone-coated 4-0 and 6-0 monoilament nylon sutures were purchased from Doccol Co. (Sharon, MA, USA). 
Isolurane was obtained from Hana Pharm (Hwaseong, Korea).
Ǥ Cy3-labeled polymersomes were prepared 
from the POEGMA-PDPA polymer or Angiopep-2-POEGMA-PDPA, previously prepared and characterized as pre-
viously described15. Four types of nanopolymersomes (Angiopep-2-POEGMA-PDPA vehicle (Brain-targeted blank 
nanopolymersomes; bt-Blank-NP), Angiopep-2-POEGMA-PDPA with carnosine (Brain-targeted carnosine-loaded 
nanopolymersomes; bt-CAR-NP), POEGMA-PDPA blank (Non-targeted vehicle nanopolymersomes; nt-Blank-NP), 
and POEGMA-PDPA with carnosine (Non-targeted carnosine-loaded nanopolymersomes; nt-CAR-NP).
For encapsulation of cargo into polymersomes (bt-CAR-NP and nt-CAR-NP), electroporation was performed 
as previously reported31. A stock solution of carnosine was ilter sterilized and loaded together with polymer-
somes into 800 µL electroporation cuvettes (BioRad; Hercules, CA, USA), to a inal concentration of 1.5 mg/mL 
carnosine and 3 mg/mL polymersomes, and electroporation was performed with an Eppendorf 2510 electropora-
tor (Hamburg, Germany) with a total of 10 pulses at 2500 V. Electroporated polymersomes were let in 4 °C over-
night to allow suicient time for the pores to close, followed by puriication via gel permeation chromatography 
to remove residual free protein, with Sepharose 4B as the mobile phase. Puriied polymersomes were assessed for 
size and shape with dynamic light scattering (DLS) and transmission electron microscopy (TEM), respectively. 
Protein encapsulation was determined via reverse-phase high-performance liquid chromatography (RP-HPLC) 
and drug encapsulation eiciency in polymersomes was calculated with a MATLAB script utilizing DLS data to 
determine the average number of drug molecules per polymersome.
      Ǥ High Performance Liquid 
Chromatography (HPLC) was performed using a Dionex Ultimate 3000 instrument (hermo Fisher Scientiic; 
Rockford, IL, USA). To detect total polymer and protein content, polymersomes were disrupted in 0.05% triluo-
roacetic acid (TFA) (Sigma-Aldrich). A multi-step gradient of HPLC grade methanol (Sigma-Aldrich) as eluent 
A and milliQ water (Merck Millipore; Burlington, MA, USA) in 0.05% triluoroacetic acid as eluent B was used 
to elute samples over 30 minutes with a C18 column (Jupiter C18 300 Å, 150 × 4.60 mm, 5 µm; Phenomenex®; 
Torrance, CA,USA) as reported previously, with a mobile phase gradient of 95% mQH2O + 0.05% TFA and 
5% MeOH + 0.05% TFA and a low rate of 1 mL/min21. Polymer content was detected using luorescence (λex: 
540 nm; λem: 560 nm). Protein content was detected using the UV/Vis channel of 220 nm. Areas under the 
detected peaks were measured using Chromeleon sotware (hermo Fisher Scientiic).
Ǥ he sample was analyzed with a 120-mW He-Ne laser at 630 nm at a controlled 
temperature of 25 °C, and the scattered light was measured at an angle of 173°. For the analysis, the sample was 
diluted with iltered PBS (pH 7) at a inal concentration of 0.2 mg/mL into a inal volume of 500 µL and then trans-
ferred into a polystyrene cuvette (DTS0012; Malvern Instruments; Malvern, UK). All DLS data were processed 
using Dispersion Technology Sotware (Malvern Instruments).
Ǥ A phosphotungstic acid (PTA) solution was used as a positive and a 
negative staining agent because of its preferential interaction with the ester groups on the poly-MPC polymers. 
he PTA staining solution was prepared by dissolving 37.5 mg of PTA in boiling distilled water (5 mL). he pH was 
adjusted to 7.4 by adding a few drops of 5 M NaOH with continuous stirring. he PTA solution was then iltered 
through a 0.2 µm ilter. 5 µL of polymersome/PBS dispersion was deposited onto glow-discharged copper grids. Ater 
1 min, the grids were blotted with ilter paper and then immersed into the PTA staining solution for 5 s for positive 
staining and 10 s for negative staining. hen, the grids were blotted again and dried under vacuum for 1 min. Grids 
were imaged using an FEI Tecnai G2 Spirit TEM microscope at 80 kV (FEI Company, Hillsbro, OR, USA).
Ǥ Experiments and procedures were performed in accordance with the institutional and international 
guidelines and regulations. All protocols for animal experiments were approved by the Institutional Animal Care 
and Use Committee (IACUC; 2016-0108A and 2016–0219A) at Hanyang University, Korea. Five-week-old male 
Sprague-Dawley rats (230–300 g), six-week-old male C57BL/6 mice (20–25 g) or male BALB/c nude mice (20–
25 g) were purchased from Koatech (Pyeongtaek, Korea). Animals were housed in a speciic-pathogen-free zone 
(12 h light/dark cycle, 23 °C, and 50% humidity) and randomly divided into the treatment groups. Investigators 
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were blind to the allocation of treatment during surgeries and outcome evaluations. A total of one hundred and 
eighty animals (Fiteen rats in each group; six groups; two models of permanent and transient ischemia) were 
used to determine the eicacy of carnosine or carnosine-loaded nanopolymersomes in rat models of ischemia. 
Sixty C57BL/6 mice were used for mouse models of transient ischemia, and eight BALB/c nude mice were used to 
conduct in vivo imaging of nanopolymersomes.
Ǥ Permanent or transient brain ischemia was induced by middle 
cerebral artery occlusion (MCAo)13. Anesthesia was induced by isolurane inhalation and maintained during the 
surgical procedure. Rectal temperature was monitored and maintained at 37 °C during surgery. he measurement 
of cerebral blood low (CBF) was performed by laser Doppler (Perimed; North Royalton, OH, USA) before and at 
the onset of MCAo, and ater reperfusion. he success of MCAo was conirmed by a drop in the regional CBF in the 
let cerebral cortex to less than 30% of pre-MCAo values32. he let common carotid artery (CCA) and the external 
carotid artery (ECA) were carefully isolated and ligated tightly with a suture. Ater the ECA branch was cauterized, 
the internal carotid artery (ICA) was isolated and the pterygopalatine artery was coagulated. To initiate the ischemia, 
a silicone-coated 4-0 nylon monoilament suture (Doccol Co.) was inserted into the CCA and advanced into the 
ICA to the origin of the MCA in rats. In the mouse model, a 6-0 nylon monoilament suture was used. he ilament 
was let in place for permanent ischemia, and for the transient model, re-perfusion was conducted by removal of the 
monoilament at 3 hours ater occlusion. Free carnosine or polymersomes in saline were administered intravenously 
through the lateral tail vein at 3 hours ater ischemia onset. In models of transient ischemia, reperfusion was initiated 
ater intravenous treatment of carnosine, polymersomes or corresponding vehicles.
Ǥ At 24 hours ater induction of ischemia, animals were 
euthanized by isolurane overdose. Brains were rapidly isolated and then cut into 1 mm sections, stained with 
triphenyltetrazolium chloride (TTC; 2%), and ixed in 4% paraformaldehyde. Each brain section was scanned to 
a digital image, and analyzed using the NIH ImageJ sotware. he infarct volume for each section was calculated 
and correction for edema was performed by the measurement of the infarcted and control hemisphere.
Ǥ Neurological functional deicit was evaluated by functional tests 
at 24 hours ater MCAo prior to brain isolation. Neurological function was scored from 0 to 18 (normal score, 0; 
maximal deicit score, 18) by neurological severity scores (NSS). he 18-point-based scale includes the following 
ive tests: spontaneous activity symmetry of movements (maximum 3 points), symmetry of hindlimbs/forelimbs 
(maximum 3 points), beam balance tests (maximum 6 points), sensory tests (maximum 2 points) and relexes and 
abnormal movements (maximum 4 points), as previously described33.
In vivoǤ In vivo luorescence imaging was conducted in BALB/c nude mice 
(20–25 g). Mice were maintained under isolurane anesthesia during the luorescence detection. Polymersomes in 
a saline suspension was injected intravenously via tail vein, and luorescence signal (λex: 520 nm, λem: 570 nm) 
from the whole mouse was monitored in IVIS Lumina XR (Xenogen Corporation Caliper; Waltham, MA, USA) 
at each time point indicated. To determine the tissue distribution of polymersomes, the luorescence intensity was 
measured in each organ. At 24 hours ater injection of polymersomes, major organs such as liver, lung, spleen, 
heart, kidney, and brain were excised and washed with saline before obtaining luorescent images.
Ǥ he number of animals to be used per group was determined using a series of 
power calculations using commercially available sotware (Janet D. Elashof, nQuery Advisor, Los Angeles, CA).
Ǥ All experimental values were expressed as mean and standard deviation (SD). Infarct 
volumes and neurological scores in graphs were presented using boxplots. Statistical signiicance between groups 
was determined by one-way ANOVA with post hoc LSD test34. In all analyses, a p < 0.05 was considered statisti-
cally signiicant.
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